GlobeNewswire by notified

Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference

Share

Daix (France), Long Island City (New York), December 16, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Frédéric Cren, Chairman, CEO and cofounder of Inventiva, has been invited to present a corporate overview, followed by a Q&A session, and will engage, with Inventiva’s leadership team, in 1x1 investor meetings at the upcoming 40th Annual J.P. Morgan Annual Healthcare Conference, being held virtually on January 10-13, 2022.

The event details are as follows:

Date:                                                Thursday, January 13, 2022
Time of the presentation:           11:15 am – 11:35 am (ET) / 5:15 pm – 5:35 pm (CET)
Time of the Q&A session:           11:35 am – 11:55 am (ET) / 5:35 pm – 5:55 pm (CET)
Live and replay link:                     Click here
Format:                                           Virtual event

The link to the event will also be available on Inventiva’s website in the “Investors – Investor Presentations” section.

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of preclinical programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained both FDA Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH. Lanifibranor is currently being evaluated in a pivotal Phase III clinical trial.

The Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases resulting in the discovery of the drug candidate cedirogant (AABV-157), an oral RORg inverse agonist. Cedirogant has reached clinical proof of concept during a Phase Ib clinical trial and is currently being evaluated in a Phase IIb clinical trial in patients with moderate to severe chronic plaque psoriasis. This collaboration enables Inventiva to receive payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from this collaboration.

Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients in 2019 and received both FDA Fast Track and Rare Paediatric Disease designation for odiparcil in MPS VI.
In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.

The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.

Contacts

Inventiva
Pascaline Clerc
VP of Global External Affairs

media@inventivapharma.com
+1 240 620 9175
Brunswick Group
Laurence Frost /
Tristan Roquet Montegon /
Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83
Westwicke, an ICR Company
Patricia L. Bank

Investor relations
patti.bank@westwicke.com
+1 415 513 1284

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Share Buyback Transaction Details January 20 – 26, 202227.1.2022 10:00:00 CET | Press release

Share Buyback Transaction Details January 20 – 26, 2022 January 27, 2022 - Wolters Kluwer today reports that it has repurchased 78,099 of its own ordinary shares in the period from January 20, 2022, up to and including January 26, 2022, for €6.9 million and at an average share price of €88.92. These repurchases are part of the share buyback program announced on November 3, 2021, under which we intend to repurchase shares for €50 million during the period starting January 3, 2022, up to and including February 21, 2022. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2022 PeriodCumulative shares repurchased in period Total consideration (€ million)Average share price (€) 2022 to date 265,483 25.0 94.18 For the above-mentioned period, we have engaged a third party to execute €50 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Association.

Cool Company Limited Update27.1.2022 09:14:12 CET | Press release

27 January 2022; Golar LNG (“Golar”) is pleased to provide a further update on the formation of Cool Company Ltd. (“CoolCo”). Reference is made to announcements on 15 December 2021 and 20 January 2022, regarding Golar’s announced execution of a Terms Agreement to separate its 8 TFDE LNG carriers into CoolCo. Based on investor feedback following the press releases made on 15 December 2021 and 20 January 2022, CoolCo has decided to launch a book building process of a private placement of $250 million (“The Private Placement”). The anticipated proceeds from the Private Placement will, together with a contemplated debt refinancing, be used to finance the acquisition of the 8 TFDE vessels from Golar, secure attractive financing and provide CoolCo with working capital to position the company for further growth. Eastern Pacific Shipping (“EPS”) has pre-subscribed and guaranteed an allocation of minimum $150 million in the contemplated private placement. The Private Placement The Private Place

Hitachi Energy achieves 100% fossil free electricity in own operations27.1.2022 09:00:00 CET | Press release

The global technology and market leader in power grids has achieved the first-step target in its Sustainability 2030 plan and steps up the pace towards carbon-neutral Zurich, Switzerland, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Hitachi Energy today announced that it has achieved the first-step target set out in its Sustainability 2030 plan – the use of 100% fossil-free electricity in its own operations1. The company is driving towards being carbon-neutral in its own operations by 20302, in line with its Purpose, ‘Advancing a sustainable energy future for all’. “By achieving 100% fossil-free electricity in our own operations, we have reduced our CO2 equivalent emissions by over 50% compared to 2019,” says Claudio Facchin, CEO of Hitachi Energy. He continued, “The Net Zero challenge is global and it’s about acting now, innovating and collaborating across countries, industries and societies. Together with customers, partners, and all stakeholders, we are advancing the world’s energy system to b

Participation notification by Blackrock Inc.27.1.2022 08:30:00 CET | Press release

Participation notification by Blackrock Inc. Brussels, 27 January 2022, 08:30 CET - According to Belgian transparency legislation (Law of May 2, 2007), BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.) recently sent to Solvay the following transparency notifications indicating that it crossed the threshold of 3%. Here is a summary of the moves: Date on which the threshold was crossed Voting rights after the transaction Equivalent financial instruments after the transaction Total January 21, 2022 3.05% 0.41% 3.46% January 24, 2022 2.93% 0.44% 3.37% The latest notification, dated January 25, 2022, contains the following information: Reason for the notification: acquisition or disposal of voting securities or voting rightsNotified by: BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.)Date on which the threshold is crossed: January 24, 2022Threshold of direct voting rights crossed: 3% downwardsDenominator: 105,876,416Additional information: The disclosure obl

Van Lanschot Kempen prepares additional covered bond programme27.1.2022 08:30:00 CET | Press release

’s-Hertogenbosch/Amsterdam, the Netherlands, 27January 2022 Van Lanschot Kempen is working on creating an additional covered bond programme with a soft bullet structure in 2022, under which any future covered bonds are expected to be issued. The new programme will allow further diversification of Van Lanschot Kempen’s debt investor base and funding profile. Media Relations: +31 203544585; mediarelations@vanlanschotkempen.com Investor Relations: +31 203544590; investorrelations@vanlanschotkempen.com About Van Lanschot Kempen Van Lanschot Kempen, a wealth manager active in Private Banking, Asset Management and Merchant Banking, aims to preserve and create wealth, in a sustainable way, for both its clients and the society of which it is part. Listed at Euronext Amsterdam, Van Lanschot Kempen is the Netherlands’ oldest independent financial services company, with a history dating back to 1737. For more information, please visit vanlanschotkempen.com This press release does not constitute a

Stolt-Nielsen Limited Reports Unaudited Results For the Fourth Quarter and Full Year 202127.1.2022 08:15:00 CET | Press release

LONDON, January 27, 2022 – Stolt-Nielsen Limited (Oslo Børs: SNI) today reported unaudited results for the fourth quarter and full year 2021. The Company reported a fourth-quarter net profit of $35.0 million, with revenue of $593.1 million, compared with a net profit of $33.5 million, with revenue of $580.9 million, in the third quarter. The net profit for the full year 2021 was $78.8 million, with revenue of $2,181.1 million, compared with a net profit from continuing operations of $39.2 million, with revenue of $1,955.1 million, in 2020. Highlights for the fourth quarter, compared with the third quarter of 2021, were: Stolt Tankers reported operating profit of $19.2 million, down from $24.1 million due to weaker COA volumes and rising voyage expenses. The Stolt Tankers Joint Service (STJS) Sailed-in Time-Charter Index reduced slightly from 0.53 to 0.51. The STJS sailed-in revenue for the quarter was $18,438 per operating day basis an average size per ship of 31,694 deadweight tonnes

PGS ASA: Q4 and Preliminary Full Year 2021 Results27.1.2022 08:00:00 CET | Press release

Improving Competitive Position in a Gradually Recovering Market Takeaways 2021 Segment Revenues and Other Income of $590.0 million, compared to $595.9 million in 2020, which included $38.8 million of Covid-19 related government grantsSegment EBITDA of $320.2 million, compared to $397.7 million in 2020, impacted by a significant change of activity mix with less MultiClient and more contract acquisitionSegment EBIT loss (excluding impairments and other charges) of $54.6 million, compared to a profit of $12.2 million in 2020Cash flow from operations of $326.6 million, compared to $366.5 million in 2020Returning to positive net cash flow generation in 2021, with cash flow before financing activities (interest payments and debt service) of $154.7 million for the full year As Reported Revenues and Other Income according to IFRS of $703.8 million and an EBIT loss of $66.2 million, compared to $512.0 million and an EBIT loss of $188.0 million, respectively, in 2020Leveraging PGS’ integrated bu